Ketorolac tromethamine impurity and preparation method thereof
By removing tromethamine under acidic conditions and catalyzed with photocatalytic oxidation, combined with liquid phase separation technology, high-purity ketorolac tromethamine impurities were prepared, which solved the RRT=0.51 in the production of ketorolac tromethamine The problem of abnormal peaks provides a basis for quality research and improves processes to ensure drug safety.
Patent Information
- Application Number
- CN202411539611.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-31
- Publication Date
- 2024-11-29
AI Technical Summary
In the prior art, there is an abnormal peak of RRT=0.51 in the production process of ketorolac tromethamine, which fails to clarify its structure and source, affecting the quality and safety of the drug.
Ketorrocyl teramyl is used as the starting material to remove teramyl under acidic conditions, and then catalyzed oxidation through photocatalytic oxidation, combined with liquid phase separation technology, the target impurities are prepared. The specific steps include dissolution, light degradation, and reduction. Pressure distillation and dilution, separation was performed using a Kromail 100-5-C18 chromatography column to achieve high purity target impurities preparation.
The purity of the target impurities prepared reaches more than 90%, clarify the impurity structure, provide a basis for quality research and process improvement, explain the abnormal peak problem in the Chinese Pharmacopoeia regulations, has positive significance for the upgrade of the Pharmacopoeia, and controllable process parameters. Raw materials are easy to obtain.
Smart Images

Figure CN119039302A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemistry, and particularly relates to a ketorolac tromethamine impurity and a preparation method thereof. Background Art
[0002] Ketorolac tromethamine was first developed by Syntex in the UK and approved for marketing in the United States in 1993. It is a nonsteroidal drug with strong analgesic activity and a non-selective cyclooxygenase (COX) inhibitor. It is converted into ketorolac in the human body and exerts its therapeutic effect. Ketorolac achieves analgesic, anti-inflammatory and antipyretic effects by blocking the cyclooxygenase or collagen-induced platelet aggregation of arachidonic acid and inhibiting the synthesis of prostaglandins (PG). In addition, ketorolac tromethamine is also used to replace opioid analgesics for short-term treatment of acute and severe pain, especially to relieve moderate to severe pain. It is mainly used clinically for postoperative analgesia and relief of symptoms such as acute renal colic, biliary colic, traumatic pain, mid-to-late stage cancer pain, toothache, and trigeminal neuralgia. Compared with traditional narcotic analgesics, ketorolac tromethamine does not directly act on opioid receptors and is non-addictive. Its analgesic effect is stronger than that of aspirin, indomethacin and naproxen, and its anti-inflammatory effect is equivalent to or better than that of indomethacin, naproxen and phenylbutazone, and it has no obvious interference with the respiratory and circulatory systems.
[0003] In the process of analyzing and studying ketorolac tromethamine, we found that the relative retention time (RRT) of the first peak of the system suitability solution prepared according to the procedures in the 2020 edition (Part II) of the Chinese Pharmacopoeia was 0.51, which was not the impurity I with RRT=0.54 mentioned in it. The system suitability solution was prepared according to the procedures in the 2020 edition (Part II) of the Chinese Pharmacopoeia, and its HPLC spectrum is as follows Figure 1 As shown; the HPLC spectrum of the system suitability solution prepared by purchasing the impurity reference substance is as follows Figure 2 Wherein, the structural formula of impurity I is as follows: .
[0004] Ketorolac tromethamine in the 2020 edition of the Chinese Pharmacopoeia (Part II): System suitability solution: Take about 30 mg of ketorolac tromethamine, place it in a 250 ml separatory funnel, add 100 ml of water to dissolve it, add 100 ml of dichloromethane and 1 ml of 1 mol / L hydrochloric acid solution, shake, and let it stand to separate. Take 1 ml of the dichloromethane layer solution, place it in a transparent borosilicate glass bottle, irradiate it in sunlight for 10 to 15 minutes, blow it dry with air or nitrogen, and add 1 ml of solvent to dissolve it.
[0005] By analyzing the production process and destructive research of ketorolac tromethamine, it is confirmed that impurity I with RRT=0.54 belongs to process impurities. The process is as follows: .
[0006] Impurity I will not be generated in the system suitability solution prepared according to the procedures in the 2020 edition of the "Chinese Pharmacopoeia" (Part II), but there are no relevant reports on the abnormal peak with RRT=0.51 generated in the solution and the mechanism of the generation of the abnormal peak.
[0007] In order to fully study the quality and properties of ketorolac tromethamine and ensure its safety, it is necessary to clarify the structure of the RRT=0.51 impurity, attribute the source and category of the impurity, and provide a basis for determining the appropriate preparation process and storage conditions during preparation research. Summary of the invention
[0008] The object of the present invention is to provide a ketorolac tromethamine impurity and a preparation method thereof.
[0009] The ketorolac tromethamine impurity of the present invention is characterized in that the structural formula is as follows: .
[0010] The method for preparing the ketorolac tromethamine impurity of the present invention comprises the following steps: (1) dissolving ketorolac tromethamine in water, adding an organic solvent and concentrated hydrochloric acid, extracting ketorolac into the organic solvent, and obtaining a ketorolac solution; (2) Placing the ketorolac solution in a light box for light degradation; (3) Evaporate the organic solvent under reduced pressure, add tetrahydrofuran to dissolve, then add methanol and water to dilute to obtain the sample solution; (4) Separating and preparing the sample solution through a preparative liquid phase to obtain a target peak collection solution; (5) The collected solution is evaporated under reduced pressure to remove methanol, and then freeze-dried to obtain the target impurity ketorolac tromethamine.
[0011] The organic solvent in step (1) is dichloromethane or ethyl acetate.
[0012] In the step (1), the mass percentage concentration of concentrated hydrochloric acid is 34-36%.
[0013] In the step (1), the ratio of ketorolac tromethamine to water, organic solvent and concentrated hydrochloric acid is 1:50-150:50-150:3-5 (g / ml / ml / ml).
[0014] In the step (2), the illumination intensity of the illumination box is 4000-5000 Lux, and the illumination time is 24-48 hours.
[0015] In the step (3), the temperature of the reduced pressure distillation is 25-35°C.
[0016] In the step (3), the ratio of ketorolac tromethamine to tetrahydrofuran, methanol and water is 1:20:20:30 (g / ml / ml / ml).
[0017] In the step (4), the conditions for preparing the liquid phase separation are: Chromatographic column: Kromail 100-5-C18, Φ30×250mm; Detection wavelength: 313nm; Mobile phase: methanol-water mixed in a volume ratio of 60:40; Flow rate: 30ml / min; Injection volume: 4.5~5.5ml.
[0018] In the step (5), the temperature for removing the organic solvent under reduced pressure is 25-35°C.
[0019] Specifically, the preparation method of ketorolac tromethamine impurities of the present invention comprises the following steps: weighing ketorolac tromethamine raw material into a reaction bottle, adding purified water, stirring to dissolve, adding organic solvent and concentrated hydrochloric acid (35±1%) under stirring, stirring for 5 minutes, transferring to a separating funnel, separating an organic layer, and obtaining a ketorolac solution; placing the ketorolac solution in a transparent borosilicate glass bottle, placing it in a light box (4000~5000Lux) for illumination for 24~48h; distilling the organic solvent from the illuminated solution under reduced pressure at 25~35°C, adding tetrahydrofuran, shaking to dissolve, and then adding methanol and purified water, mixing evenly to obtain a sample solution; the sample solution is separated and prepared by using a preparative liquid phase, and the conditions for the preparative liquid phase separation preparation are as follows: chromatographic column: Kromail 100-5-C18, Φ30×250mm; detection wavelength: 313nm; mobile phase: methanol-water = 60:40 (V / V); flow rate: 30ml / min; injection volume: 5±0.5ml; collect the ketorolac tromethamine target impurity peak solution, evaporate the methanol under reduced pressure at 25~35℃, and then freeze-dry to obtain the ketorolac tromethamine target impurity.
[0020] The reaction principle of the present invention is as follows: .
[0021] The invention uses ketorolac tromethamine as a starting material, removes tromethamine under acidic conditions, then performs photocatalytic oxidation, and obtains target impurities through separation and purification by preparative liquid phase.
[0022] The beneficial effects produced by the present invention are: The purity of the target impurity prepared by the present invention reaches more than 90%, and can be used as a reference product for quality research; the present invention confirms the impurity structure and obtains the reference product, which can provide a basis and help for prescription screening and process improvement; the present invention explains the abnormal peak problem appearing in the "Chinese Pharmacopoeia" regulations, which has positive significance for the upgrading of the "Chinese Pharmacopoeia"; the preparation method of the present invention uses easily available raw materials, controllable process parameters, and mild reaction. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is the HPLC spectrum of the system suitability solution prepared in accordance with the regulations in the 2020 edition (Part II) of the Chinese Pharmacopoeia.
[0024] Figure 2 HPLC profile of a system suitability solution prepared for a commercially available ketorolac tromethamine impurity reference.
[0025] Figure 3 The HPLC spectrum of the impurities of ketorolac tromethamine prepared in Example 1 of the present invention.
[0026] Figure 4 The mass spectrum of the ketorolac tromethamine impurity prepared in Example 1 of the present invention.
[0027] Figure 5 This is the NMR-H spectrum of the ketorolac tromethamine impurity prepared in Example 1 of the present invention. DETAILED DESCRIPTION
[0028] The specific implementation modes of the present invention are further described below in conjunction with embodiments.
[0029] Example 1 The preparation method of the ketorolac tromethamine impurity comprises the following steps: Weigh 0.5g of ketorolac tromethamine raw material into a reaction bottle, add 50ml of purified water, stir to dissolve, add 50ml of dichloromethane and 2.0ml of concentrated hydrochloric acid (35±1%) under stirring, stir for 5min, transfer to a separatory funnel, separate the organic layer; place the organic layer in a transparent borosilicate glass bottle, put it in a light box (4500±500Lux) for 24h; evaporate the organic solvent under reduced pressure at 30℃ after light exposure, add 10ml of tetrahydrofuran, shake to dissolve, then add 10ml of methanol and 15ml of purified water, mix well, and obtain a sample solution, the target peak in HPLC is 0.94%; The sample solution was separated and prepared by preparative liquid phase separation. The conditions for preparative liquid phase separation were as follows: Chromatographic column: Kromail 100-5-C18, Φ30×250mm; Detection wavelength: 313nm; Mobile phase: methanol-water = 60:40 (V / V); Flow rate: 30ml / min; Injection volume: 5±0.5ml.
[0030] The target impurity peak solution was collected, methanol was evaporated under reduced pressure at 30°C, and then freeze-dried to obtain the target impurity with an HPLC content of 92.98%; ESI-MS: m / z=272.08582 ([M+H] + ); 1 H-NMR (CD3OD, 600MHz):δ ppm : 3.71-3.48 (2H,m), 4.67-4.47 (2H,m), 6.15 (1H,brs), 6.86 (1H,s), 7.55-7.41 (2H,m), 7.63-7.54 (1H,m), 7.87-7.70 (2H,m).
[0031] The HPLC profile of ketorolac tromethamine impurities is shown in Figure 3 The data of each peak in the figure are shown in Table 1; the mass spectrum of ketorolac tromethamine impurity is shown in Figure 4 The NMR-H spectrum of ketorolac tromethamine impurity is shown in Figure 5 .
[0032] Table 1 HPLC data of ketorolac tromethamine impurities
[0033] Example 2 Weigh 0.5g of ketorolac tromethamine raw material into a reaction bottle, add 25ml of purified water, stir to dissolve, add 50ml of dichloromethane and 1.5ml of concentrated hydrochloric acid (35±1%) under stirring, stir for 5min, transfer to a separatory funnel, separate the organic layer; place the organic layer in a transparent borosilicate glass bottle, put it in a light box (4500±500Lux) for 48h; evaporate the organic solvent under reduced pressure at 35℃ after light exposure, add 10ml of tetrahydrofuran, shake to dissolve, then add 10ml of methanol and 15ml of purified water, mix well, and obtain a sample solution, the target peak in HPLC is 1.04%; The sample solution was separated and prepared by using a preparative liquid phase, and the conditions for the separation and preparation of the preparative liquid phase were the same as those in Example 1; The target impurity peak solution was collected, methanol was evaporated under reduced pressure at 25°C, and then freeze-dried to obtain the target impurity with an HPLC content of 94.25%.
[0034] Example 3 Weigh 0.5g of ketorolac tromethamine raw material into a reaction bottle, add 75ml of purified water, stir to dissolve, add 75ml of dichloromethane and 2.5ml of concentrated hydrochloric acid (35±1%) under stirring, stir for 5min, transfer to a separatory funnel, separate the organic layer; place the organic layer in a transparent borosilicate glass bottle, put it in a light box (4500±500Lux) for 36h; evaporate the organic solvent under reduced pressure at 25℃ after light exposure, add 10ml of tetrahydrofuran, shake to dissolve, then add 10ml of methanol and 15ml of purified water, mix well, and obtain a sample solution, the target peak in HPLC is 1.02%; The sample solution was separated and prepared by using a preparative liquid phase, and the conditions for the separation and preparation of the preparative liquid phase were the same as those in Example 1; The target impurity peak solution was collected, methanol was evaporated under reduced pressure at 35°C, and then freeze-dried to obtain the target impurity with an HPLC content of 91.72%.
[0035] Example 4 Weigh 0.5g of ketorolac tromethamine raw material into a reaction bottle, add 50ml of purified water, stir to dissolve, add 25ml of dichloromethane and 2.0ml of concentrated hydrochloric acid (35±1%) under stirring, stir for 5min, transfer to a separatory funnel, separate the organic layer; place the organic layer in a transparent borosilicate glass bottle, put it in a light box (4500±500Lux) for 24h; evaporate the organic solvent under reduced pressure at 30℃ after light exposure, add 10ml of tetrahydrofuran, shake to dissolve, then add 10ml of methanol and 15ml of purified water, mix well, and obtain a sample solution, the target peak in HPLC is 0.95%; The sample solution was separated and prepared by using a preparative liquid phase, and the conditions for the separation and preparation of the preparative liquid phase were the same as those in Example 1; The target impurity peak solution was collected, methanol was evaporated under reduced pressure at 35°C, and then freeze-dried to obtain the target impurity with an HPLC content of 92.27%.
[0036] Example 5 Weigh 0.5g of ketorolac tromethamine raw material into a reaction bottle, add 75ml of purified water, stir to dissolve, add 50ml of dichloromethane and 2.5ml of concentrated hydrochloric acid (35±1%) under stirring, stir for 5min, transfer to a separatory funnel, separate the organic layer; the organic layer is placed in a transparent borosilicate glass bottle, placed in a light box (4500±500Lux) for 36h, evaporate the organic solvent under reduced pressure at 25℃ after light exposure, add 10ml of tetrahydrofuran, shake to dissolve, then add 10ml of methanol and 15ml of purified water, mix well, and obtain a sample solution, the target peak in HPLC is 0.98%; The sample solution was separated and prepared by using a preparative liquid phase, and the conditions for the separation and preparation of the preparative liquid phase were the same as those in Example 1; The target impurity peak solution was collected, methanol was evaporated under reduced pressure at 30°C, and then freeze-dried to obtain the target impurity with an HPLC content of 93.54%.
[0037] Example 6 Weigh 0.5g of ketorolac tromethamine raw material into a reaction bottle, add 50ml of purified water, stir to dissolve, add 50ml of ethyl acetate and 2.0ml of concentrated hydrochloric acid (35±1%) under stirring, stir for 5min, transfer to a separatory funnel, separate the organic layer; place the organic layer in a transparent borosilicate glass bottle, put it in a light box (4500±500Lux) for 24h; evaporate the organic solvent under reduced pressure at 30℃ after light exposure, add 10ml of tetrahydrofuran, shake to dissolve, then add 10ml of methanol and 15ml of purified water, mix well, and obtain a sample solution, the target peak in HPLC is 0.92%; The sample solution was separated and prepared by using a preparative liquid phase, and the conditions for the separation and preparation of the preparative liquid phase were the same as those in Example 1; The target impurity peak solution was collected, methanol was evaporated under reduced pressure at 30°C, and then freeze-dried to obtain the target impurity with an HPLC content of 92.57%.
[0038] Example 7 Weigh 0.5g of ketorolac tromethamine raw material into a reaction bottle, add 75ml of purified water, stir to dissolve, add 50ml of ethyl acetate and 2.5ml of concentrated hydrochloric acid (35±1%) under stirring, stir for 5min, transfer to a separatory funnel, separate the organic layer; place the organic layer in a transparent borosilicate glass bottle, put it in a light box (4500±500Lux) for 36h; evaporate the organic solvent under reduced pressure at 25℃ after light exposure, add 10ml of tetrahydrofuran, shake to dissolve, then add 10ml of methanol and 15ml of purified water, mix well, and obtain a sample solution, the target peak in HPLC is 0.96%; The sample solution was separated and prepared by using a preparative liquid phase, and the conditions for the separation and preparation of the preparative liquid phase were the same as those in Example 1; The target impurity peak solution was collected, methanol was evaporated under reduced pressure at 30°C, and then freeze-dried to obtain the target impurity with an HPLC content of 93.02%.
[0039] The present invention is described in detail above in conjunction with the embodiments, but the contents described are only preferred embodiments of the present invention and cannot be considered to limit the scope of implementation of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the scope of the patent coverage of the present invention.
Claims
1. A ketorolac tromethamine impurity, It is characterized in that The structural formula is as follows: 。 2. A method for preparing the ketorolac tromethamine impurity according to claim 1, It is characterized in that The following steps are involved: (1) dissolving ketorolac tromethamine in water, adding an organic solvent and concentrated hydrochloric acid, extracting ketorolac into the organic solvent, and obtaining a ketorolac solution; (2) Placing the ketorolac solution in a light box for light degradation; (3) Evaporate the organic solvent under reduced pressure, add tetrahydrofuran to dissolve, then add methanol and water to dilute to obtain the sample solution; (4) Separating and preparing the sample solution through a preparative liquid phase to obtain a target peak collection solution; (5) The collected solution is evaporated under reduced pressure to remove methanol, and then freeze-dried to obtain the target impurity ketorolac tromethamine.
3. The method for preparing the ketorolac tromethamine impurity according to claim 2, It is characterized in that The organic solvent in step (1) is dichloromethane or ethyl acetate.
4. The method for preparing the ketorolac tromethamine impurity according to claim 2, Features: In the step (1), the mass percentage concentration of concentrated hydrochloric acid is 34-36%.
5. The method for preparing ketorolac tromethamine impurities according to claim 2, It is characterized in that In the step (1), the ratio of ketorolac tromethamine to water, organic solvent and concentrated hydrochloric acid is 1:50-150:50-150:3-5 (g / ml / ml / ml).
6. The method for preparing ketorolac tromethamine impurities according to claim 2, Features: In the step (2), the illumination intensity of the illumination box is 4000-5000 Lux, and the illumination time is 24-48 hours.
7. The method for preparing ketorolac tromethamine impurities according to claim 2, It is characterized in that In the step (3), the temperature for distilling off the organic solvent under reduced pressure is 25-35°C.
8. The method for preparing ketorolac tromethamine impurities according to claim 2, It is characterized in that In the step (3), the ratio of ketorolac tromethamine to tetrahydrofuran, methanol and water is 1:20:20:30 (g / ml / ml / ml).
9. The method for preparing ketorolac tromethamine impurities according to claim 2, It is characterized in that In the step (4), the conditions for preparing the liquid phase separation are: Chromatographic column: Kromail 100-5-C18, Φ30×250mm; Detection wavelength: 313nm; Mobile phase: methanol-water mixed in a volume ratio of 60:40; Flow rate: 30ml / min; Injection volume: 4.5~5.5ml.
10. The method for preparing ketorolac tromethamine impurities according to claim 2, It is characterized in that In the step (5), the temperature for distilling off methanol under reduced pressure is 25-35°C.
Citation Information
Patent Citations
Preparation method of ketorolac tromethamine impurity I
CN118666850A
A subcutaneous pharmaceutical preparation comprising insulin(s) and an Anti-inflammatory agent to reduce tissue inflammation response in diabetic patients.
WO2019046952A1
Cited By
Method for detecting impurity content in ketorolac tromethamine gel plaster
CN120254138A
